Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) EPS (Basic) (2020 - 2023)

Terns Pharmaceuticals' EPS (Basic) history spans 4 years, with the latest figure at -$0.29 for Q4 2023.

  • For Q4 2023, EPS (Basic) fell 70.59% year-over-year to -$0.29; the TTM value through Dec 2023 reached -$1.27, up 25.73%, while the annual FY2025 figure was -$1.03, 8.04% up from the prior year.
  • EPS (Basic) reached -$0.29 in Q4 2023 per TERN's latest filing, up from -$0.42 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $8.45 in Q4 2020 to a low of -$37.82 in Q3 2020.
  • Average EPS (Basic) over 4 years is -$6.28, with a median of -$0.44 recorded in 2021.
  • The largest YoY upside for EPS (Basic) was 98.76% in 2021 against a maximum downside of 106.75% in 2021.
  • A 4-year view of EPS (Basic) shows it stood at $8.45 in 2020, then tumbled by 106.75% to -$0.57 in 2021, then skyrocketed by 70.18% to -$0.17 in 2022, then plummeted by 70.59% to -$0.29 in 2023.
  • Per Business Quant, the three most recent readings for TERN's EPS (Basic) are -$0.29 (Q4 2023), -$0.42 (Q3 2023), and -$0.25 (Q2 2023).